#Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/JWR4VsS5kP @cochranecollab #hypertension
RT @CochraneHTN: #Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/a8wOdYjEw9 @cochranecoll…
RT @CochraneHTN: #Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/a8wOdYjEw9 @cochranecoll…
RT @CochraneHTN: #Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/a8wOdYjEw9 @cochranecoll…
RT @CochraneHTN: #Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/a8wOdYjEw9 @cochranecoll…
#Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/a8wOdYjEw9 @cochranecollab #hypertension
#Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/a8wOdYjEw9 #CochraneEvidence #hypertension https://t.co/s8kX7ImigB
#Cochrane review Blood pressure lowering efficacy of aliskiren now avail in Chinese: https://t.co/BimnSYHCfS #CochraneEvidence #hypertension https://t.co/fHH7WheN2c
@NephRodby @KatieKwonMD @wittykidney @Rush_Nephrology (Sorry) any trial data to suggest it lowers hard outcomes? https://t.co/tTo5XJjiUZ suggests it lowers BP, but nothing on CV/renal outcomes
RT @KFSHRC_Research: Blood pressure lowering efficacy of renin inhibitors for primary #hypertension https://t.co/vhLOAOdic6 https://t.co/d2…
Blood pressure lowering efficacy of renin inhibitors for primary #hypertension https://t.co/vhLOAOdic6 https://t.co/d273Rkn2zw
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/FDzzHSjSPm ...estudios de 8 semanas de duración
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/FDzzHSjSPm ...estudios de 8 semanas de duración
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/FDzzHSjSPm ...estudios de 8 semanas de duración
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/FDzzHSjSPm ...estudios de 8 semanas de duración
(Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/FDzzHSjSPm ...estudios de 8 semanas de duración
ICYMI - UPDATED #Cochrane review: Blood pressure lowering efficacy of renin inhibitors for primary #hypertension: https://t.co/3y3bgcX0Ic https://t.co/BDRZSEkGrz
Eficacia hipotensora del aliskirén Cochrane https://t.co/3H1dszaSYs
RT @DougSalzwedel: UPDATED #Cochrane review: Blood pressure lowering efficacy of renin inhibitors for primary #hypertension: https://t.co/p…
UPDATED #Cochrane review: Blood pressure lowering efficacy of renin inhibitors for primary #hypertension: https://t.co/pIdXex7q44 https://t.co/92RxleIRZT
Blood pressure lowering efficacy of renin inhibitors for primary h... https://t.co/ng2W1iUZxN
UPDATED #Cochrane review: Blood pressure lowering efficacy of renin inhibitors for primary #hypertension: https://t.co/3y3bgcX0Ic https://t.co/aliilQ4iGu
RT @eturnermd1: Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the…
RT @CochraneLibrary: Current #CochraneEvidence indicates that aliskiren lowers #BP compared to placebo, but effect is dose-dependent: https…
Current #CochraneEvidence indicates that aliskiren lowers #BP compared to placebo, but effect is dose-dependent: https://t.co/DgsrpFWfBO
Aliskireno es otro de esos fármacos en busca de indicación https://t.co/YO04Yb7uP0
RT @air_garcia: Los inhibidores de renina (ej aliskiren) no aportan nada nuevo en tratamiento de HTA https://t.co/5LWWed2Fz8
Los inhibidores de renina (ej aliskiren) no aportan nada nuevo en tratamiento de HTA https://t.co/5LWWed2Fz8
RT @opentrials: Great to see FDA documents being used in systematic reviews: https://t.co/EiBdVc5Lkw Search FDA docs: https://t.co/8UGFRqB…
RT @opentrials: Great to see FDA documents being used in systematic reviews: https://t.co/EiBdVc5Lkw Search FDA docs: https://t.co/8UGFRqB…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @eturnermd1: Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the…
RT @opentrials: Great to see FDA documents being used in systematic reviews: https://t.co/EiBdVc5Lkw Search FDA docs: https://t.co/8UGFRqB…
RT @eturnermd1: Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the…
RT @eturnermd1: Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the…
RT @eturnermd1: Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the…
This is a great step. I routinely read FDA briefing report for the new product https://t.co/QveFu9Owms
RT @eturnermd1: Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the…
RT @opentrials: Great to see FDA documents being used in systematic reviews: https://t.co/EiBdVc5Lkw Search FDA docs: https://t.co/8UGFRqB…
@eturnermd1 @eturnermd1 Hi Erick - strange, it's working this end! Here's the PubMed link: https://t.co/88Gc368PS5
Priority in systematic reviews of approved drugs shd B (1) FDA review and (2) publ'd lit (often incomplete & spun), not the other way around https://t.co/mT480EQv7m
RT @opentrials: Great to see FDA documents being used in systematic reviews: https://t.co/EiBdVc5Lkw Search FDA docs: https://t.co/8UGFRqB…
Great to see FDA documents being used in systematic reviews: https://t.co/EiBdVc5Lkw Search FDA docs: https://t.co/8UGFRqBhdI #pharma #FDA https://t.co/j1UGUExejT
Blood pressure lowering efficacy of renin inhibitors for primary hypertension. - PubMed - NCBI ハードエンドポイントなし? https://t.co/oUsmUNOEwO
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/obEtfuewSU
Does #Aliskiren effectively lower blood pressure? https://t.co/YL2v1GKeRJ https://t.co/5dHlgyNcn5
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/obEtfuewSU
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
*Sigh* Oh dear. Novartis making us all look bad again. When will PharmaCos realise that euphemisms & sleight-of-hand don't cut it any more? https://t.co/4dMD2oKdM0
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @rincondesisifo: (Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/obEtfuewSU
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @evidpediatria: Blood pressure lowering efficacy of aliskiren https://t.co/K1qxCIOIBZ https://t.co/WGyck1l6e5
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd... https://t.co/eTDzNcnFM5 by #bengoldacre via @c0nvey https://t.co/KdKsS2PaT9
RT @benmeg: Great to see @cochranecollab using regulatory documents (CSRs + medical reviews) in their systematic reviews: https://t.co/8tYY…
.@cochranecollab However, we still have the problem of trial sponsors (hi @Novartis) withholding important safety outcome data https://t.co/izTd4x4eY9
Great to see @cochranecollab using regulatory documents (CSRs + medical reviews) in their systematic reviews: https://t.co/8tYYPDvoIR https://t.co/LQIHLxUGxu
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @CochraneUK: Lack of access to Case Narratives means Cochrane can't accurately depict harms of aliskiren #alltrials @bengoldacre https:/…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…